Anti PD-1 and PDL-1 Immunotherapy in the Treatment of Advanced Non- Small Cell Lung Cancer (NSCLC): A Review on Toxicity Profile and its Management.

摘要: The better understanding of immunology and antitumor immune responses have prompted the development novel immunotherapy agents like PD-1 checkpoint inhibitors (anti-PD-1 anti- PDL-1 antibodies) that improve capacity system to acknowledge delete tumors, including lung cancer. Currently, two anti-PD-1 (nivolumab pembrolizumab) one PD-L1 (MPDL-3280A) are in advanced stages or metastatic non-small cell cancer (NSCLC). Among these, nivolumab demonstrated a survival benefit versus docetaxel refractory squamous NSCLC, reporting 41% reduction risk death (median overall survival: 9.2 6.0 months; objective response rate: 20% 9%), safety profile than standard-of-care chemotherapy (grade 3-4 adverse events: 7% 55%). However, enhancement targeting specific regulatory checkpoints is associated with toxicity different from related traditional chemotherapeutic molecularly targeted therapies. success ongoing evaluation/identification treatment these immunerelated side effects. Herein, first clinical results reviewed, focusing on its management.